Lantus and Hyperbilirubinaemia - a phase IV clinical study of FDA data


Hyperbilirubinaemia is found among people who take Lantus, especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months.

The phase IV clinical study analyzes which people take Lantus and have Hyperbilirubinaemia. It is created by eHealthMe based on reports of 175,171 people who have side effects when taking Lantus from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 03, 2022

175,171 people reported to have side effects when taking Lantus.
Among them, 52 people (0.03%) have Hyperbilirubinaemia.

What is Lantus?

Lantus has active ingredients of insulin glargine recombinant. It is often used in diabetes. eHealthMe is studying from 176,422 Lantus users for its effectiveness, alternative drugs and more.

What is Hyperbilirubinaemia?

Hyperbilirubinaemia (excess of bilirubin in the blood) is found to be associated with 1,432 drugs and 1,021 conditions by eHealthMe.

Number of Lantus and Hyperbilirubinaemia reports submitted per year:

Could Lantus cause Hyperbilirubinaemia?

Time on Lantus when people have Hyperbilirubinaemia *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 33.33 %
  • 6 - 12 months: 33.33 %
  • 1 - 2 years: 33.33 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hyperbilirubinaemia when taking Lantus *:

  • female: 43.14 %
  • male: 56.86 %

Age of people who have Hyperbilirubinaemia when taking Lantus *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 7.5 %
  • 20-29: 2.5 %
  • 30-39: 5.0 %
  • 40-49: 12.5 %
  • 50-59: 30.0 %
  • 60+: 42.5 %

Common drugs people take besides Lantus *:

  1. Humalog: 10 people, 19.23%
  2. Pantoprazole: 9 people, 17.31%
  3. Synthroid: 9 people, 17.31%
  4. Novolog: 8 people, 15.38%
  5. Metformin: 7 people, 13.46%
  6. Lipitor: 6 people, 11.54%
  7. Protonix: 6 people, 11.54%
  8. Lasix: 6 people, 11.54%
  9. Amlodipine: 6 people, 11.54%
  10. Januvia: 5 people, 9.62%

Common side effects people have besides Hyperbilirubinaemia *:

  1. Anaemia (lack of blood): 15 people, 28.85%
  2. Jaundice - Yellow Skin (a yellowish pigmentation of the skin): 10 people, 19.23%
  3. Fatigue (feeling of tiredness): 9 people, 17.31%
  4. Aspartate Aminotransferase Increased: 8 people, 15.38%
  5. Alanine Aminotransferase Increased: 7 people, 13.46%
  6. Blood Creatinine Increased: 7 people, 13.46%
  7. Weakness: 6 people, 11.54%
  8. Nausea (feeling of having an urge to vomit): 6 people, 11.54%
  9. Hypotension (abnormally low blood pressure): 5 people, 9.62%
  10. Hyperglycemia (high blood sugar): 5 people, 9.62%

Common conditions people have *:

  1. High Blood Pressure: 10 people, 19.23%
  2. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 9.62%
  3. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 9.62%
  4. Gout (uric acid crystals building up in the body): 4 people, 7.69%
  5. Neuropathy Peripheral (surface nerve damage): 4 people, 7.69%
  6. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 5.77%
  7. Hepatitis C: 3 people, 5.77%
  8. Inflammation: 2 people, 3.85%
  9. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 2 people, 3.85%
  10. Gastroduodenal Ulcer: 2 people, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Lantus and have Hyperbilirubinaemia?

Check whether Hyperbilirubinaemia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Hyperbilirubinaemia and when was it recovered:

Expand to all the drugs that have ingredients of insulin glargine recombinant:

Alternative drugs to, pros and cons of Lantus:

Common Lantus side effects:

Browse all side effects of Lantus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Hyperbilirubinaemia treatments and more:

COVID vaccines that are related to Hyperbilirubinaemia:

Common drugs associated with Hyperbilirubinaemia:

All the drugs that are associated with Hyperbilirubinaemia:

Common conditions associated with Hyperbilirubinaemia:

All the conditions that are associated with Hyperbilirubinaemia:

How the study uses the data?

The study uses data from the FDA. It is based on insulin glargine recombinant (the active ingredients of Lantus) and Lantus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: